

Message

From: Ex. 5 Deliberative Process (DP)

Sent: 5/5/2021 8:50:12 PM

To: v];

CC: Ex. 6 Personal Privacy (PP)

Subject: RE: P-20-0005

I am checking the record. Ex. 5 Deliberative Process (DP)

Ex. 5 Deliberative Process (DP)

Ex. 6 Personal Privacy (PP)

US EPA's New Chemicals Division

Washington DC, 20460

Ex. 6 Personal Privacy (PP)

From: Ex. 6 Personal Privacy (PP)

Sent: Wednesday, May 05, 2021 3:29 PM

To: Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

Cc: Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

Subject: RE: P-20-0005

Ex. 6 Personal Privacy (PP)

Ex. 5 Deliberative Process (DP)

Ex. 6 Personal Privacy (PP)

US EPA's New Chemicals Division

Washington DC, 20460

Ex. 6 Personal Privacy (PP)

From: Ex. 6 Personal Privacy (PP)

Sent: Wednesday, May 05, 2021 3:20 PM

To: Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

Cc: Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

Subject: FW: P-20-0005

Same comment: Please tally up the HOF cases and let's discuss at our next management meeting.

ED_006153A_00002368-00001

Ex. 6 Personal Privacy (PP)

New Chemicals Division
USEPA/OCSP/OPPT

Ex. 6 Personal Privacy (PP)

From: Watson, Sara Beth <SWatson@steptoe.com>

Sent: Monday, May 3, 2021 11:22 AM

To: Ex. 6 Personal Privacy (PP)

Cc:

Subject: RE: P-20-0005

Ex. 6 Personal Privacy (PP)

I am writing again to follow up on the status of the risk assessment for P-20-0005. While I understand that there has been some progress, EPA has yet to produce a risk assessment that can be used to finalize a consent order. This PMN has been pending for over 18 months. It has been 360 days since additional information was submitted to EPA. I am urgently requesting a call to establish a pathway for completion of this review.

Regards,
Sara Beth

Sara Beth Watson
SWatson@steptoe.com

Step toe

202 429 6460 direct
202 261 0533 fax

Step toe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036
www.steptoe.com

This message and any attached documents contain information from the law firm Steptoe & Johnson LLP that may be confidential and/or privileged. If you are not the intended recipient, please do not read, copy, distribute, or use this information. If you have received this transmission in error, please notify the sender immediately by reply e-mail and then delete this message.

From: Watson, Sara Beth

Sent: Wednesday, February 24, 2021 3:14 PM

To: Ex. 6 Personal Privacy (PP)

Cc:

Subject: RE: P-20-0005

Ex. 6 Personal Privacy (PP)

I am writing to follow up on my previous emails and our very brief phone conversation last Friday. On Friday you indicated that you would check on the status of the risk assessment and schedule a call. As I have not heard from EPA regarding scheduling a call, I wanted to check with you. The submitter has been waiting since May 2020 for EPA to complete the risk assessment for this substance. We have been given several expected completion dates for the risk assessment in the past eight months (June 2020 through January 2021). When each date arrived EPA had not completed the assessment. We are now approaching the end of the ninth month with no indication of when the review may be completed. I look forward to speaking with you as soon as possible.

Regards,
Sara Beth

Sara Beth Watson

ED_006153A_00002368-00002

SWatson@steptoe.com

Steptoe

202 429 6460 direct
202 261 0533 fax

Steptoe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036
www.steptoe.com

This message and any attached documents contain information from the law firm Steptoe & Johnson LLP that may be confidential and/or privileged. If you are not the intended recipient, please do not read, copy, distribute, or use this information. If you have received this transmission in error, please notify the sender immediately by reply e-mail and then delete this message.

From: Watson, Sara Beth

Sent: Thursday, February 18, 2021 6:25 PM

To: **Ex. 6 Personal Privacy (PP)**

Cc:

Subject: RE: P-20-0005

Ex. 6 Personal Privacy (PP)

I am writing to follow up on the status of the risk assessment for P-20-0005. When we spoke in January you were hopeful that progress would be made on this issue by mid-February; however it does not appear that has happened. It has been over 280 days since the additional information was provided to EPA. I would like to schedule a call with you as soon as possible to discuss the status of the risk assessment.

Regards,
Sara Beth

Sara Beth Watson
SWatson@steptoe.com

Steptoe

202 429 6460 direct
202 261 0533 fax

Steptoe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036
www.steptoe.com

This message and any attached documents contain information from the law firm Steptoe & Johnson LLP that may be confidential and/or privileged. If you are not the intended recipient, please do not read, copy, distribute, or use this information. If you have received this transmission in error, please notify the sender immediately by reply e-mail and then delete this message.

From: Watson, Sara Beth

Sent: Friday, January 22, 2021 6:05 PM

To: **Ex. 6 Personal Privacy (PP)**

Cc:

Subject: P-20-0005

Ex. 6 Personal Privacy (PP)

Thank you again for your time last week to discuss the status of the risk assessment for P-20-0005. It has been over 250 days since the additional information was provided to EPA and while we appreciate the agency

ED_006153A_00002368-00003

is very busy, we hope that the reorganization and other factors you noted on the call will provide a timely completion of the risk assessment for this substance.

A draft consent order has been prepared, but can go no further until the risk assessment review is completed. Potential customers are eager to use the substance in the US as the substance has important uses in manufacturing, and provides a sustainable, multifunctional additive for plastics and composite products. The substance is approved in Canada for uses similar to those identified in the PMN and US manufacturers would like access to the same technological advantages.

Regards,
Sara Beth

Sara Beth Watson
SWatson@steptoe.com

Steptoe

202 429 6460 direct
202 261 0533 fax

Steptoe & Johnson LLP
1330 Connecticut Avenue, NW
Washington, DC 20036
www.steptoe.com

This message and any attached documents contain information from the law firm Steptoe & Johnson LLP that may be confidential and/or privileged. If you are not the intended recipient, please do not read, copy, distribute, or use this information. If you have received this transmission in error, please notify the sender immediately by reply e-mail and then delete this message.